
ESCMID

ECCMID

Final Programme

Vienna, Austria
22 – 25 April 2017



Committees

ESCMID Executive Committee



Mario Poljak
Ljubljana, Slovenia
President



Jesús Rodríguez-Baño
Seville, Spain
President-elect and Secretary General



Murat Akova
Ankara, Turkey
Past-President and
Communications & Publications Officer



Alexander W. Friedrich
Groningen, Netherlands
Treasurer



Maurizio Sanguinetti
Rome, Italy
Professional Affairs Officer



Evelina Tacconelli
Tübingen, Germany
Education Officer



Annelies Zinkernagel
Zurich, Switzerland
Scientific Affairs Officer



Giuseppe Cornaglia
Verona, Italy
International Affairs Director



Michel Drancourt
Marseille, France
NMNI Editor-in-Chief



Christian G. Giske
Stockholm, Sweden
EUCAST Chairperson



William W. Hope
Liverpool, United Kingdom
ESCMID Guidelines Director



Winfried V. Kern
Freiburg, Germany
ECCMID Programme Director



Leonard Leibovici
Petah-Tiqva, Israel
CMI Editor-in-Chief

Committees

ECCMID Programme Committee (EPC)
Winfried V. Kern, Freiburg, Germany, *ECCMID Programme Director*
Murat Akova, Ankara, Turkey
Miriam José Alvarez Martinez, Barcelona, Spain
Joop E. Arends, Utrecht, Netherlands
Sevtap Arikan-Akdagli, Ankara, Turkey
Robert A. Bonomo, Cleveland, United States
Francesco Castelli, Brescia, Italy
Thierry Calandra, Lausanne, Switzerland
Jon S. Friedland, London, United Kingdom
Alexander W. Friedrich, Groningen, Netherlands
Niels Frimodt-Moller, Copenhagen, Denmark
Carolina Garcia Vidal, Barcelona, Spain
Hans Hirsch, Basel, Switzerland
Gunnar Kahlmeter, Växjö, Sweden
Jan A.J.W. Kluytmans, Breda, Netherlands
Dimitrios P. Kontoyiannis, Houston, TX, United States
Amel Letaief, Sousse, Tunisia
Kristine Morch, Bergen, Norway
Mark Patrick Nicol, Cape Town, South Africa
Elisabet Nielsen, Uppsala, Sweden
Hanna M. Nohynek, Helsinki, Finland
Dan Otelea, Bucharest, Romania
Lucia Pastore Celentano, Stockholm, Sweden
Luisa Maria Vieira Peixe, Porto, Portugal
Eli Perencevich, Iowa City, United States
Mario Poljak, Ljubljana, Slovenia
Jesús Rodríguez-Baño, Seville, Spain
Holger Rohde, Hamburg, Germany
Maurizio Sanguinetti, Rome, Italy
Katja Seme, Ljubljana, Slovenia
Mark Everett Shirtliff, Baltimore, United States
Maria Souli, Athens, Greece
Jean-Paul Stahl, Grenoble, France
Arnfinn Sundsfjord, Tromsö, Norway
Yupin Suputtamongkol, Bangkok, Thailand
Evelina Tacconelli, Tübingen, Germany
Kate Templeton, Edinburgh, United Kingdom
Ursula Theuretzbacher, Vienna, Austria
Jean-Francois Timsit, Paris, France
Francoise Van Bambeke, Brussels, Belgium
Linos Vandekerckhove, Ghent, Belgium
Annelies Zinkernagel, Zurich, Switzerland

ESCMID Education Subcommittee (ES)
Evelina Tacconelli, Tübingen, Germany, *Chairperson*
Cansu Çimen, Istanbul, Turkey
Giovanni Delogu, Rome, Italy
Önder Ergönül, Istanbul, Turkey
Eskild Petersen, Aarhus, Denmark
Laurent Poirel, Fribourg, Switzerland
Céline Pulcini, Nancy, France
Kaisu Hellevi Rantakokko-Jalava, Turku, Finland
Agnes Maria Sonnevend, Al Ain, United Arab Emirates
Maria Souli, Athens, Greece
Thea-Christin Zapf, Marburg, Germany, *Ad hoc*
Snjezana Zidovec Lepej, Zagreb, Croatia

ESCMID Publication Subcommittee (PS)
Murat Akova, Ankara, Turkey, *Chairperson*
Leonard Leibovici, Petah-Tiqva, Israel
Michel Drancourt, Marseille, France
Fiona Macnab, London, United Kingdom

ESCMID Scientific Affairs Subcommittee (SAS)
Annelies Zinkernagel, Zurich, Switzerland, *Chairperson*
Oliver James Dyar, Stockholm, Sweden
Andreas H. Groll, Münster, Germany
Luigi Gradoni, Rome, Italy
Adriana Vince, Zagreb, Croatia
Mona Johannessen, Tromsö, Norway
Carolina Garcia Vidal, Barcelona, Spain
Souha S. Kanj, Beirut, Lebanon
Gilbert Greub, Lausanne, Switzerland
Frederic Laurent, Lyon, France

ESCMID Professional Affairs Subcommittee (PAS)
Maurizio Sanguinetti, Rome, Italy, *Chairperson*
Emmi Andersson, Stockholm, Sweden
Ferry Hagen, Nijmegen, Netherlands
Polona Maver Vodicar, Ljubljana, Slovenia
Surbhi Malhotra-Kumar, Antwerp, Belgium
Joanna Verran, Manchester, United Kingdom
Matthias Willmann, Tübingen, Germany
Hilpi Rautelin, Uppsala, Sweden
Nur Benzonana, Istanbul, Turkey
Julia Anna Bielicki, London, United Kingdom
Elena Carrara, Tübingen, Germany
Achilleas Gikas, Iraklio, Creta, Greece
Alejandro Martin-Quiros, Madrid, Spain
Malgorzata Mikulska, Genoa, Italy
Carlos Palos, Loures, Portugal
Jean-Paul Stahl, Grenoble, France

Parity Commission (PC)
Maurizio Sanguinetti, Rome, Italy, *Chairperson*
Evelina Tacconelli, Tübingen, Germany, *Chairperson*
Angela Huttner, Geneva, Switzerland
Alexandra Mailles, Saint-Maurice, France
Chrysanthi Skevaki, Marburg, Germany

P1361 **Novarifyn, a novel antimicrobial peptide rapidly active against multi drug-resistant *Staphylococcus aureus* and *Acinetobacter baumannii***
L. Katvars (Aberdeen, United Kingdom), D. Mercer, D. O'Neil*

P1362 **Phase II clinical study of oral lascufloxacin in community-acquired pneumonia**
T. Kato (Frankfurt, Germany), M. Odajima, S. Kohno*

P1363 **Phase II clinical study of lascufloxacin intravenous infusion in community-acquired pneumonia**
T. Kato (Frankfurt, Germany), M. Odajima, S. Kohno*

P068 12:30 – 13:30
New discoveries against Gram-negatives

P1364 ***In vitro* activity of the novel fluorocycline TP-6076 against carbapenem non-susceptible *Acinetobacter baumannii***
H. Seifert (Cologne, Germany), D. Stefanik, J. Sutcliffe, P. Higgins*

P1365 **TP-6076 is active against carbapenem- and polymyxin-resistant Enterobacteriaceae and *Acinetobacter baumannii* isolates in the FDA-CDC antimicrobial isolate bank panels**
J. Newman (Watertown, United States), C. Fyfe, B. Close, G. LeBlanc*

P1366 ***Arenicin peptides*: broad-spectrum activity and a dual mode of action**
A. Elliott (Brisbane, Australia), J. Huang, S. Neve, I. Edwards, J. Zuegg, A. Kavanagh, A. Cain, C. Boinett, M. Butler, M. Blaskovich, M. Cooper*

P1367 **POL7001 is highly efficacious in the murine neutropenic lung-infection model**
G. Dale (Allschwil, Switzerland), J. Teague, P. Thommes, P. Warn, J. Hansen, C. Vingsbo Lundberg, F. Bernardini, D. Obrecht*

P1368 **Design, synthesis and *in vivo* profiling of novel inhibitors of *P. aeruginosa* multi-virulence factor regulator (MvfR)**
D. Andreotti (Verona, Italy), A. Felici, M. Antolini, L. Rahme, M. Negri, V. Garrido-Estevez, R. Zahler, M. Pucci, A. Feriani, D. Andreotti, E. Dalla Benetta*

P1369 **Comparative *in vitro* antimicrobial activities of CSA-142 and CSA-192, the second generation of ceragenins, with CSA-13**
O. Oyardı (Ankara, Turkey), C. Bozkurt Guzel*

P1370 ***In vitro* and *in vivo* activity of theaflavin-epicatechin combinations versus multidrug-resistant *Acinetobacter baumannii***
J. Betts (Guildford, United Kingdom), M. Hornsey, D. Wareham, R. La Ragione*

P1371 **The result of structure activity relationship**
J. Park (Yongin-Si, South Korea), W. Im, S. Choi, H. Sung, J. Moon, J. Choi*

P1371A **Efficacy results of DA-7010**
J. Park (Yongin-Si, South Korea), W. Im, S. Choi, H. Sung, J. Moon, H. Lee, M. Lee, J. Choi*

P1372 ***In vitro* and *in vivo* efficacy of LpxC inhibitor, CHIR-090, alone or combined with colistin against *Pseudomonas aeruginosa* biofilm**
J. Tan (Singapore, Singapore)*

P1373 ***In vivo* efficacy of a novel bacterial topoisomerase inhibitor**
N. Ooi (Cheshire, United Kingdom), A. Salisbury, C. Charrier, N. Chaffer-Malam, E. Moyo, T. Duffy, V. Savage, J. Cheung, R. Metzger, N. Stokes, M. Craighead, I. Cooper, A. Ratcliffe, A. Lyons, E. Dick, R. Walker, K. Blades, J. Kirkham, S. Best, H. Butler*

P1374 **Biological characterization of a novel bacterial DNA gyrase and topoisomerase IV inhibitor**
N. Ooi (Cheshire, United Kingdom), C. Charrier, N. Chaffer-Malam, E. Moyo, R. Newman, D. Hine, V. Savage, J. Cheung, N. Stokes, M. Craighead, I. Cooper, A. Ratcliffe, A. Lyons, E. Dick, R. Walker, K. Blades, J. Kirkham, H. Butler, S. Best, A. Salisbury*

P069 13:30 – 14:30
Enterococcal infections: epidemiology and resistance

P1375 **Epidemiology of enterococci isolated from an infection in Belgium**
K. Loens (Antwerp, Belgium), M. Ieven, E. Yusuf, H. Goossens*

P1376 **Rare mechanisms of resistance in Belgian enterococci identified by WGS**
K. Loens (Antwerp, Belgium), V. Matheeussen, A. Verlinden, M. Ieven, E. Yusuf, B. Xavier, S. Malhotra-Kumar, H. Goossens*

P1377 **Differences in resistance and virulence between various sequence types of CC17 vancomycin-resistant *Enterococcus faecium* clinical isolates**
A. Sieńko (Białystok, Poland), P. Wieczorek, D. Ojdana, P. Majewski, A. Wieczorek, P. Sacha, E. Tryniszewska*

ECCMID 2017 - Abstract result

Gelen Kutusu

eccmidabstracts eccmidabstracts@escmid.org escmidbasel.onmicrosoft.com üzerinden

Alıcı: ben

20 Oca 2017 Cum 19:40

İngilizce Türkçe İletiyi çevir İngilizce için kapat

27th ECCMID Vienna, Austria 22 – 25 April 2017

The congress of ESCMID

Basel, 20 January 2017

Dear özlem oyardı
Title: Comparative in-vitro antimicrobial activities of CSA-142 and CSA-192, the second generation of ceragenins, with CSA-13
Abstract number: 5228

Thank you very much for having submitted an abstract to ECCMID, 22 – 25 April 2017, Vienna, Austria. The response to the call was extremely high.

The ECCMID 2017 Programme Committee is pleased to inform you that the above-mentioned abstract has been accepted for ECCMID 2017. Session type: Paper Poster Session

The name of your session and the exact date and time will be communicated until the end of the month.

If you are not the presenting author, please forward this notification to the presenting author and inform the Abstract Team at eccmidabstracts@escmid.org.

The final scientific programme including abstract titles will be available online on www.eccmid.org in early February 2017; however, the abstracts themselves will be released 12 April 2017.

If you have not yet registered for the meeting, please do so now online on the ECCMID website. Please note that abstracts without a registered presenting author will not be part of ECCMID 2017. The presenting author must register before 28 February 2017 to ensure publication of the abstract in the ESCMID eLibrary and on the congress website. If you are unable to attend please advise us of your withdrawal before 28 February 2017.

The early registration fee applies until 26 January 2017.

Again, we congratulate you on the acceptance of your abstract and are looking forward to seeing you in Vienna. If you have any questions or need assistance, please feel free to contact us at eccmidabstracts@escmid.org.

Yours sincerely,
ECCMID 2017 Abstract Team
On behalf of the ECCMID 2017 Programme Committee

27th ECCMID Vienna, Austria 22 – 25 April 2017

The congress of ESCMID

27th ECCMID Vienna, Austria 22 – 25 April 2017
The congress of ESCMID

P1369 **Comparative in-vitro antimicrobial activities of CSA-142 and CSA-192, the second generation of ceragenins, with CSA-13**

Ozlem Oyardı[1], Cagla Bozkurt Guzel[1]

[1]Istanbul university, Pharmaceutical microbiology,

Background: Ceragenins are cationic derivatives of colic acid and have broad antimicrobial activities. They are similar to cationic antimicrobial peptides (AMP) due to their cationic and amphiphilic properties. These molecules have a number of advantages over AMPs, most importantly they are resistant to proteases. The lipid structure of the hydrophobic segments of the ceragenins allows this molecule to settle more easily into the membrane. A large number of ceragenins, mainly CSA-13 (cationic steroid antibiotics), have been synthesized and studied. This study was aimed to investigate the antimicrobial activities of, not only CSA-13, but also CSA-142 and CSA-192 as second generation of ceragenins.

Material/methods: The antimicrobial activities of CSA-13, CSA-142 and CSA-192 were studied against twenty strains of *Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus* and *Candida albicans* isolated from various specimens. MICs, MBCs and MFCs were determined by microdilution method according to CLSI.

Results: According to the table, MIC_{50} and MIC_{90} values differ from 0.5 to 16 µg/ml and 1 to 32 µg/ml. The most remarkable MIC_{50} values were shown against *S. aureus*. Overall, CSA-13 showed the lowest MIC values against all microorganisms. Furthermore, CSA-142 and CSA-192 as second generation CSAs have meaningful activities against tested microorganisms. The antifungal effects of these studied CSAs were similar. MBCs or MFCs were found equal or twice greater than MICs.

Conclusions: As a result, not only CSA-13, but also CSA-142 and CSA-192 as second generation CSA's have significant antimicrobial effects. But future studies should be performed to correlate safety, efficacy and pharmacokinetic parameters of these molecules.

Table: *In vitro* antimicrobial activities of CSA-13, CSA-142 and CSA-192

Microorganisms	CSA-13		CSA-142		CSA-192	
	MIC_{50} (µg/ml)	MIC_{90} (µg/ml)	MIC_{50} (µg/ml)	MIC_{90} (µg/ml)	MIC_{50} (µg/ml)	MIC_{90} (µg/ml)
E. coli	4	4	8	16	16	16
A. baumannii	8	8	16	32	16	32
P. aeruginosa	8	16	16	16	16	32
S. aureus	0.5	1	4	4	2	2
C. albicans	2	4	8	8	8	8